Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease?
- 1 June 2006
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 101 (6) , 1260-1267
Abstract
Few data are available on chronic hepatitis C (CHC) in elderly patients. The aim of this study was to compare the features and severity of CHC and the efficacy/safety of antiviral therapy in patients 80 yr old, and to determine the usefulness of biochemical markers (Fibrotest-Fibrosure/ActiTest [FT-AT]) in aged patients. This was a retrospective study with two groups of patients: Group 1: prospective cohort including all hepatitis C virus patients from our institution (N = 4,182); Group 2: all consecutive patients who had FT-AT performed in France between 2002 and 2004 (N = 33,738). A total of 6,865 patients ≥65 yr old was included (Group 1 = 881, Group 2 = 5,984). Group 1: patients ≥65 had a longer duration of and a higher age at infection, more genotype 1, and a history of transfusion ( p < 0.001). Among the 2,169 patients who underwent liver biopsy, bridging fibrosis (F2,F3,F4) was more frequent in patients ≥65 yr old, regardless of the duration of infection. In multivariate analysis, ages at biopsy and at infection were associated with F2,F3,F4. Discovery of CHC by a complication was more frequent in patients ≥65 yr ( p < 0.001). One hundred seventy patients ≥65 yr received antiviral therapy. A sustained virologic response was obtained in 45% of patients ≥65 yr treated with pegylated interferon/ribavirin. Group 2: At FT, 58% of patients >80 yr, 37% of patients between 65 and 80 yr, and 14% of patients p < 0.001) had cirrhosis. Patients >80 yr (43%) with cirrhosis had nonelevated alanine amino transferase (ALT), compared with 31% of patients p < 0.001). In patients ≥65 yr, CHC is more severe and presents with lower ALT than in younger patients. Treatment is effective. Biochemical markers seem particularly useful as a noninvasive alternative to liver biopsy in this population.Keywords
This publication has 30 references indexed in Scilit:
- Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical responseJournal of Gastroenterology, 2004
- Biochemical Surrogate Markers of Liver Fibrosis and Activity in A Randomized Trial of Peginterferon Alfa–2B and RibavirinHepatology, 2003
- Noninvasive Prediction of Fibrosis in Patients With Chronic Hepatitis CHepatology, 2003
- Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patientsAIDS, 2003
- Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approachJournal of Hepatology, 2001
- Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experienceHepatology, 2000
- An algorithm for the grading of activity in chronic hepatitis CHepatology, 1996
- Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis CHepatology, 1994
- Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitisJournal of Hepatology, 1992
- Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitisHepatology, 1991